First Time Loading...

Atara Biotherapeutics Inc
NASDAQ:ATRA

Watchlist Manager
Atara Biotherapeutics Inc Logo
Atara Biotherapeutics Inc
NASDAQ:ATRA
Watchlist
Price: 0.671 USD -3.45% Market Closed
Updated: Dec 11, 2023

Intrinsic Value

Valuation History
Atara Biotherapeutics Inc

Historical Profit
Current Valuation
Price & Value Correlation
Value CAGR
Calculating
Intrinsic Value History...

Our system is conducting in-depth analyses to map out the stock's valuation journey. Thank you for waiting.

Fundamental Analysis

Financials
NEW
NEW

Balance Sheet Decomposition
Atara Biotherapeutics Inc

Current Assets 119m
Cash & Short-Term Investments 102m
Receivables 200k
Other Current Assets 16.1m
Non-Current Assets 70.1m
PP&E 63.8m
Other Non-Current Assets 6.3m
Current Liabilities 79.1m
Accounts Payable 6.5m
Accrued Liabilities 60.1m
Other Current Liabilities 12.5m
Non-Current Liabilities 161m
Other Non-Current Liabilities 161m
Efficiency
Fundamental Scores

ATRA Profitability Score
Profitability Due Diligence

Atara Biotherapeutics Inc's profitability score is 16/100. The higher the profitability score, the more profitable the company is.

ROIC is Increasing
Positive Revenue Growth Forecast
Negative 1-Year Revenue Growth
Declining ROE
16/100
Profitability
Score

Atara Biotherapeutics Inc's profitability score is 16/100. The higher the profitability score, the more profitable the company is.

ATRA Solvency Score
Solvency Due Diligence

Atara Biotherapeutics Inc's solvency score is 35/100. The higher the solvency score, the more solvent the company is.

Low D/E
Short-Term Solvency
Long-Term Solvency
Low Altman Z-Score
35/100
Solvency
Score

Atara Biotherapeutics Inc's solvency score is 35/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

ATRA Price Targets Summary
Atara Biotherapeutics Inc

Wall Street analysts forecast ATRA stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ATRA is 4.019 USD with a low forecast of 0.404 USD and a high forecast of 13.65 USD.

Lowest
Price Target
0.404 USD
40% Downside
Average
Price Target
4.019 USD
499% Upside
Highest
Price Target
13.65 USD
1 934% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

ATRA Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

ATRA Return Decomposition
Main factors of price return

What is price return decomposition?

ATRA Price
Atara Biotherapeutics Inc

1M 1M
+161%
6M 6M
-65%
1Y 1Y
-84%
3Y 3Y
-97%
5Y 5Y
-98%
10Y 10Y
-94%
Annual Price Range
0.671
52w Low
0.23
52w High
5.46
Price Metrics
Average Annual Return -16.14%
Standard Deviation of Annual Returns 29.89%
Max Drawdown -99%
Shares Statistics
Market Capitalization 68.4m USD
Shares Outstanding 101 100 000
Percentage of Shares Shorted 8.21%

ATRA News

Last Video News
Atara Biotherapeutics Inc

Other Videos

Company Profile

Atara Biotherapeutics Inc Logo
Atara Biotherapeutics Inc

Country

United States of America

Industry

Biotechnology

Market Cap

68.4m USD

Dividend Yield

0%

Description

Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which pioneers the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. The company is headquartered in South San Francisco, California and currently employs 578 full-time employees. The company went IPO on 2014-10-16. The firm is a developer of T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune disease. Its platform leverages the biology of EBV T cells and has the capability to treat a range of EBV-driven diseases or other serious diseases through engineered chimeric antigen receptors (CARs) or T-cell receptors (TCRs). The Company’s pipeline products include Tab-cel, ATA188, ATA2271, ATA3271 and ATA3219. The Company’s T-cell immunotherapy, tab-cel (tabelecleucel), is in Phase III development for patients with EBV-driven post-transplant lymphoproliferative disease (EBV+ PTLD) who have failed rituximab or rituximab plus chemotherapy, as well as other EBV-driven diseases. Its ATA188 is a T-cell immunotherapy for the treatment of multiple sclerosis.

Contact

CALIFORNIA
South San Francisco
611 Gateway Blvd Ste 900
+16502788930.0
http://www.atarabio.com/

IPO

2014-10-16

Employees

578

Officers

Pres, CEO & Director
Dr. Pascal Touchon D.V.M.
Exec. VP & CFO
Mr. Utpal Koppikar M.B.A.
Sr. VP & Gen. Counsel
Mr. K. Amar Murugan
Exec. VP and Global Head of R&D
Dr. Jakob Dupont M.D.
Chief Technical Officer
Ms. Charlene Banard
Chief Scientific Officer
Dr. Anhco Nguyen
Show More
VP of Investor Relations & Fin.
Eric Hyllengren
Head of Corp. Communications
Kerry Beth Daly
Chief People Officer
Ms. Amie Krause
Exec. VP
Mr. Joseph Newell
Show Less

See Also

Discover More